Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2021;32(3):243-8
Cut-Off Value of Serum Uric Acid for Development of Gout Disease in Patients with Multiple Co-Morbidities
Authors Information

1. Division of Rheumatology, Department of Internal Medicine, Pamukkale University Faculty of Medicine, Denizli, Turkey

2. Department of Internal Medicine, Pamukkale University Faculty of Medicine, Denizli, Turkey

3. Department of Public Health, Pamukkale University Faculty of Medicine, Denizli, Turkey

F Ulutas, NY Çelikyürek, V Çobankara, A Bozdemir, CA Yaşar 

References
  1. Richette P, Bardin T. Gout. Lancet 2010;375:318-28.
  2. Birlik M, Gurler O, Akar S, Sarı I, Onen F, Akkoc N. The prevalence of gout in an urban area of Izmir, Turkey: a population-based epidemiological study. Int J Clin Pract 2014;68:775-82.
  3. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout. Adv Ther 2015;32:31-41.
  4. Soysal P. Comment on "Serum uric acid is associated with better executive function in men but not in women: Baseline assessment of the ELSA-Brasil study". Exp Gerontol 2017;1:96-9.
  5. Hall AP, Barry PE, Dawber TR, Mc Namara PM. Epidemiology of gout and hyperuricemia. A long-term population study. Am J Med 1967;42;27-37.
  6. Campion EW, Glynn RJ, Delabry LO. Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med 1987;82:421-6.
  7. Johnson R, Bakris G, Borghi C, Chonchol M, Feldman D, Lanaspa M, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis 2018;71:851-65.
  8. Feig D, Mazzali M, Kang D, Nakagawa T, Price K, Kannelis J, et al. Serum uric acid: a risk factor and a target for treatment? J Am Soc Nephrol 2006;17(4 Suppl 2):S69-73.
  9. Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E. Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology (Oxford) 2018;57:1358-63.
  10. Köttgen A, Albrecht E, Teumer A, Vitart V, Krumsiek J, Hundertmark C, et al. Genome-wide association analyses identify 18 new loci associated with serum urate concentrations. Nat Genet 2013;45:145-54.
  11. Neogi T, Jansen TL, Dalbeth N, Fransen J, Scuhumacher R, Berendsen D, et al. Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015;74:1789-98.
  12. Majdan M, Borys O. Gout and comorbidities associated with hyperuricemia. Ann Acad Med Stetin 2010;56(Suppl 1):34-9.
  13. Karis E, Crittenden DB, Pillinger MH. Hyperuricemia, gout, and related comorbidities: cause and effect on a two-way Street. South Med J 2014;107:235-41.
  14. Takir M, Kostek O, Ozkok A, Elcioglu OC, Bakan A, Erek A, et al. Lowering Uric Acid With Allopurinol Improves Insulin Resistance and Systemic Inflammation in Asymptomatic Hyperuricemia. J Investig Med 2015;63:924-9.
  15. El-bassossy HM, Shaltout HA. Allopurinol alleviates hypertension and proteinuria in high fructose, high salt and high fat induced model of metabolic syndrome. Transl Res 2015;165:621-30.
  16. Öztürk MA, Kaya A, Şenel S, Dönmez S, Balkarlı A, Çobankara V, et al. Demographic and clinical features of gout patients in Turkey: a multicenter study. Rheumatol Int 2013;33:847-52.
  17. Zhu Y, Pandya BJ, Choi HK. Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med 2012;125:679-87.e1.
  18. Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. Am J Transl Res 2020;12:3167-81.
  19. Riches P, Wright AF, Ralston SH. Recent insights into the pathogenesis of hyperuricaemia and gout. Hum Mol Genet 2009;18:R177-84.
  20. Major TJ, Dalbeth M, Stahl EA, Merriman TR. An update on the genetics of hyperuricaemia and gout. Nat Rev Rheumatol 2018;14:341-53.
  21. Hakoda M, Kasagi F. Increasing trend of asymptomatic hyperuricemia under treatment with urate-lowering drugs in Japan. Mod Rheumatol 2019;29:880-4.